There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > ORGANIZATION
ORGANIZATION
- High-Priced Drugs Should Be Discussed Carefully Based on Characteristics of Diseases and Treatments: JMA Exec
July 1, 2021
- More than 80% of Pharmacists Feel Impact of Generic Supply Delays on Business: Survey
June 23, 2021
- Patient Group Wants More R&D Spending on Pancreatic Cancer
June 15, 2021
- Saitama-Based Hospital Group Introduces Formulary in 18 Therapeutic Areas, Aims to Spread Know-How in Region
June 15, 2021
- FPMAJ Urges Caution with Market Expansion Re-Pricing, Says Add’l Indications Now Seen as Price Cut Risk
June 14, 2021
- FPMAJ Drug Price Report Rebuts Issues Raised over Cost-Plus Method, PMP and More
June 14, 2021
- PhRMA Posts Its Position on Japan CEA Scheme on Website
June 11, 2021
- Eisai’s Akana Re-Elected as FPMAJ’s Drug Pricing Chief
June 11, 2021
- Terumo’s Mimura Elected New Medical Devices Chief; Reimbursement Debate Ahead for SaMD
June 9, 2021
- Experts Eye Macroeconomic Indexing of Drug Costs to Keep Innovation Afloat: INES Proposal
May 31, 2021
- Ken Suzuki Returns to JPWA Reins after 2 Years
May 28, 2021
- JPMA Positive on Use of Clinical Research Data in Submissions, but Wary of Funding Database
May 26, 2021
- Ken Suzuki Likely to Come Back as JPWA Chief after 2 Years
May 25, 2021
- JPMA Will Work towards Price Maintenance for On-Patent Medicines: New President
May 24, 2021
- Eisai’s Okada Elected as JPMA Chief, Daiichi Sankyo’s Manabe to Head FPMAJ
May 21, 2021
- JPMA Has “Different View” from US Govt on COVID-19 Vaccine IP Waiver
May 10, 2021
- EFPIA Issues Proposals for Japanese CEA System, Says “Cannot Accept” Expansion without Corrective Steps
April 21, 2021
- Regulations for DX, Pre-Symptomatic Disease Up for JPMA Committee Discussion
April 20, 2021
- Asia Trade Groups Discuss Regional Differences in Nonclinical Evaluations of Human Cell Products
April 20, 2021
- JGA Bitterly Reprimands Kobayashi Kako for Application Document Fabrication
April 20, 2021
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…